Who is sponsoring NCT05110417?

NCT05110417 is sponsored by Eastern Virginia Medical School.

What drugs are being tested in NCT05110417?

Interventions in NCT05110417: Pyridostigmine Bromide 60 Milligrams (mg).

What condition does NCT05110417 study?

NCT05110417 studies Dysphonia, Spastic, Dysphonia, Laryngeal Dystonia.

Is NCT05110417 still recruiting?

NCT05110417 is currently status unknown. Last updated 27 July 2022.

Last reviewed 2022-07-27 · How we verify

NCT05110417

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Reversal of Botulinum Neurotoxin Injection Related Dysphonia With Pyridostigmine

Status unknown Phase 4 Last updated 27 July 2022

What this trial tests

Phase 4 trial testing Pyridostigmine Bromide 60 Milligrams (mg) in Dysphonia, Spastic in 10 participants. Status unknown.

Timeline

20 May 2021

Primary endpoint
31 December 2022

1 June 2023

Quick facts

Lead sponsor	Eastern Virginia Medical School
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	10
Start date	20 May 2021
Primary completion	31 December 2022
Estimated completion	1 June 2023
Sites	1 location across United States

Drugs / interventions tested

Pyridostigmine Bromide 60 Milligrams (mg) — full drug profile →

Conditions studied

Dysphonia, Spastic — all drugs for Dysphonia, Spastic →
Dysphonia — all drugs for Dysphonia →
Laryngeal Dystonia — all drugs for Laryngeal Dystonia →

Sponsor

Eastern Virginia Medical School

Who can join

Adults 21 to 100, any sex, with Dysphonia, Spastic or Dysphonia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the effects of pyridostigmine (Mestinon) on patient vocal outcomes after undergoing laryngeal botulinum neurotoxin (BoNT) injections, which is a standard treatment for spasmodic dysphonia. Pyridostigmine (Mestinon) has been used for treatment of BoNT overdose, and it is our hope that it will be beneficial in the management of post BoNT breathy phase.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Eastern Virginia Medical School trials

Trials by the same sponsor.

NCT07224893 — Once-Daily vs Twice-Daily Insulin Glargine in Pregestational Diabetes Management · Phase 4 · not yet recruiting
NCT07119398 — Oxytocin/Foley vs. Oxytocin for Induction in Patients With PPROM · Phase 4 · recruiting
NCT06867861 — Effect of Fiber Supplementation on the Need for Medication With Gestational Diabetes · NA · recruiting
NCT06274398 — Rectal Insert TAF/EVG Pre-Exposure Prophylaxis (RITE PrEP) Study · Phase 1 · completed
NCT06087913 — Safety and PK Multi-dose Study of TAF/EVG Vaginal Insert · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05110417 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Eastern Virginia Medical School
Last refreshed: 27 July 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05110417.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing